Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
TF .. look back through the list of RNS’s .. I just did, and can’t see any reason to suggest they don’t keep shareholders informed?
Empty.. if it is Ichor exiting, I’d actually like to thank them for the pivotal role they have had in getting scancell to where it is now .. the Scib1 phase 1/2 trial produced some fantastic results .. it’s just a shame the fda never sanctioned the trial in the US.
The move to needle free delivery for immunobody vaccines was a big risk but looks to be proving a good one!
Scancell is a tiny fellowship of scientists trying to solve problems in ways nobody else has tried yet.
The focus for scancell should always be on the science and on the people on the other end of the delivery device and certainly not me , a shareholder.
They succeed, I succeed .. simple as that.
Take care all..
Deja vu .. we have been here before with city financial when they dumped millions of shares on the market for 3p .. nothing to do with scancell, but was certainly a great opportunity!
I for one don’t want scancell to start pushing out news in reaction to the ‘market’ .. or to appease any insecurity felt by anyone!
To Focus on their work is what I expect and that seems to be what they are doing ..
However, saying that, a (due) Lindy Durrant interview with an update on this progress can’t be far away? Perhaps..
Take care all ..
Slide 12 may help with your understanding ..
https://www.scancell.co.uk/Data/Sites/1/media/docspres/agm-presentationnovember-2022_final.pdf
This was from the agm last year.
Take care ..
It’s when you read other research like this that you really understand that ‘safe immunotherapy’ is not an easy achievement … and also is an insight as to the experience of Christian Ottensmeier!
https://news.liverpool.ac.uk/2022/05/06/new-discovery-could-help-combat-side-effects-of-cancer-immunotherapy/?
Take care all ..
It’s important to remember these are results from only 8 weeks in !!
As there are no other options for these patients there really is no ‘standard of care’ comparison. ..
Are the early results promising ? I’d go with Christian Ottensmeier on that one..
Also worth a thought, anyone considering going on modi1 as part of the trial… would this published data help their decision making process ? Stable and safe are good early results !
Without patients you can’t run any trial?
Take care all !
There could also be further milestone payments achieved from Genmab? Judging by Scancells understanding of science to date .. I’m guessing they will achieve something !?
Who knows .. only my opinion as ever ..
Take care all ..
Scancell soldiers on … a great RNS and it looks like LD and teams’ understanding of the tumour micro environment is being demonstrated !
The safety aspect is astonishing and remember, these are mono therapy results !!
Will be fascinating to see what adding a checkpoint inhibitor does for the patients who’s immune system just needs that little more help to tip the scales in favour of the patients !!
Very well done scancell ..
Also .. it looks like creating t-cell therapies targeting the modi1 epitopes might get a green light on the back of these early results too !
Keep going scancell !!
Take care all ..
Berm .. We live in a time of incredible scientific advancement .. I’m certainly not the first to be wishing hard for things to happen faster than they can !!
Best wishes to all in similar circumstances!!
Take care ..
Hi berm!
Thanks for this .. much appreciated.. I’ll definitely have a look .. main issue for him is hes 84 and trials I’ve looked at for fibrosis have age ranges usually up to 80 ..
Main thing is he’s comfortable and at home.
Apologies for the off topic but thanks again Berm ..
Take care all ..
Hi Cleaner !
We certainly know that CEPI are well aware of scancell .. but as crumb’s says I too get the feeling that scancell are looking at other options perhaps ..
Re Covidity ..
This trial was a triumph for a tiny Oxford based research company .. a demonstration that this tiny biotech designed, manufactured, delivered and ran a phase 1 trial … not next door but on the other side of the world !!
Scalable , affordable, stable and … effective !?
Blimey eh ..
Granted larger trials needed to back up the initial results .. but I’ve got to say again .. very well done scancell!
Take care all !